Compare Immunovant Inc. Common Stock (IMVT) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nomura Holdings Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 4.4× Immunovant Inc. Common Stock's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Nomura Holdings Inc for 55 Days on average.
| IMVT | NMR | |
|---|---|---|
Market Cap | $6.25B | $27.55B |
Volume | 1,755,411 | 782,470 |
Sector | Health | Financials |
52-Week High | $44.96 | $10.86 |
52-Week Low | $17.03 | $6.73 |
Typical Hold Time | 1 Days | 55 Days |
Enterprise Value | $5.35B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nomura Holdings (NMR) trades at $9.59, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.66T to $1.98T projected for 2026, net income margin of 20.4%, and attractive valuation ratios including P/E of 11.33. Recent news highlights technical pattern recognition and inclusion on Zacks Strong Buy lists, though cash flow trends show operational challenges.
NMR presents a mixed outlook with undervalued fundamentals against bearish technicals. Investment opportunity lies in discounted valuation and earnings momentum, but risks include negative operating cash flows, rising debt-to-asset ratios, and inconsistent earnings performance. Analyst consensus leans cautious with 67% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
